Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Coloplast Major Shareholding Notification 2012

Jul 26, 2012

3358_mrq_2012-07-26_be2e90ae-7591-40c1-8cc8-6269ba27c98f.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Announcement No. 8/2012 26 July 2012

Major shareholder changes her holding of shares in Coloplast

Pursuant to section 29 of the Danish Securities Trading Act, we hereby announce that Coloplast has been informed that Ms. Benedicte Find holds 3.56% of the share capital and 5.32% of the votes in Coloplast A/S.

Ms. Benedicte Find's combined interests are:

279,000 A shares of each DKK 5.00 1,325,186 B shares of each DKK 5.00

equivalent to a nominal value of DKK 8,020,930.

Lene Skole Executive Vice President, CFO

For further information, please contact

Investors and analysts

Lene Skole Executive Vice President, CFO Tel. +45 4911 1700

Ian S.E. Christensen Vice President, Investor Relations Tel. +45 4911 1800/+45 4911 1301 Email: [email protected]

Henrik Nord Investor Relations Manager Tel. +45 4911 1800/+45 4911 3108 Email: [email protected]

Press and the media

Ulla Lundhus Media Relations Manager Tel. +45 4911 1929 Email: [email protected]

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2012-7 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 7,500 people.